MetaCap

ImmuCell Corporation (ICCC)

NASDAQ: ICCCHealth CareBiotechnology: In Vitro & In Vivo Diagnostic SubstancesUSD

10.92-0.27 (-2.41%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

ICCC stock chart

Technical analysis

Key statistics

All statistics
Market cap
$99.28M
52-week range
4.67 – 12.10
Day range
10.31 – 11.25
Volume / Avg
18.75K / 13.44K
Beta
—

52-week range

$4.67$12.10

ICCC stock today

ImmuCell (ICCC) closed at $10.92 on Nov 20, down 2.41% (-$0.27), versus the S&P 500's 3.70% decline. At this level, ICCC sits near the top of its 52-week range of $4.67 to $12.10: 9.8% below the high, set on Jul 14, 2026 and 133.8% above the low. ICCC is up 77.6% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 133.3%.

ImmuCell trades at 57.5x its trailing twelve-month earnings per share of $0.19.

Summary generated from market data by MetaCap's automated system. Methodology

About ImmuCell

Company profile

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that improves the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments, Scours and Mastitis. The company offers First Defense, an orally delivered scours preventive product for calves with claims against E.

Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
CEO
Mr. Paul F. Olivier Te Boekhorst
Headquarters
Portland, ME
Employees
73
IPO year
1987

Financial highlights

Full financials

In fiscal 2025, ImmuCell generated $27.6 million in revenue, up 4.3% from fiscal 2024, its 2nd consecutive year of revenue growth. ImmuCell reported a net loss of $1.0 million, compared with a loss of $2.2 million a year earlier. Gross margin was 41.4% (up from 30.0%) and operating margin 6.0%.

ImmuCell annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$27.64M$26.49M$17.47M$18.57M$19.24M
Growth+4.34%+51.64%-5.90%-3.51%+25.43%
Net income$-1.04M$-2.16M$-5.77M$-2.49M$-78.29K
EPS (diluted)$-0.12$-0.26$-0.75$-0.32$-0.01

Earnings

Earnings history
Last reported (Sep/2026)
Nov 12, 2026
EPS actual vs est.
$0.10 vs —

ICCC news

All ICCC news

ImmuCell peers

Health Care sector
ICCC peer companies
CompanyPrice% ChgMarket capCompare
IMDXInsight Molecular Diagnostics Inc.1.97+18.67%$80.88Mvs ICCC
NNNNAnbio Biotechnology Class A3.32-9.04%$145.72Mvs ICCC
VNRXVolitionRX Limited0.1621-1.58%$5.85Mvs ICCC
TRIBTrinity Biotech plc ADR6.24+13.76%$5.07Mvs ICCC
BMRABiomerica Inc.1.08-0.92%$4.97Mvs ICCC
CDIOCardio Diagnostics Holdings Inc.1.60-3.03%$4.74Mvs ICCC
QCLSQ/C Technologies Inc.0.2784-6.01%$2.40Mvs ICCC
VRAXVirax Biolabs Group Limited0.3319-12.89%$446.40Kvs ICCC

Indexes, lists and sector

ImmuCell stock FAQ

What is ImmuCell's stock price today?

ICCC last traded at $10.92 as of Nov 20, 4:00 PM EST, down 2.41% on the day. Prices are delayed at least 15 minutes.

Does ImmuCell pay a dividend?

No. ImmuCell does not currently pay a regular cash dividend.

What is ICCC's P/E ratio?

ICCC trades at a trailing P/E ratio of 57.47.

Who is ImmuCell's CEO?

Mr. Paul F. Olivier Te Boekhorst is the chief executive officer of ImmuCell Corporation, which has about 73 employees.

Has ICCC ever split its stock?

Yes. The most recent ICCC stock split was a 1-for-100 split on Jul 25, 1990.

What is the ICCC 52-week high?

The 52-week high for ICCC is $12.10 and the 52-week low is $4.67. The stock is currently 9.8% below its high.

Compare ICCC